Monday, February 24, 2025 9:00:07 PM
So in the end, it's the same number of shares going out the door.
So the "massive dilution" you reference is the SAME, whether Advent is paid in shares, or someone buys the shares to provide the cash to pay the bills from the company. So there is no benefit to LP to keep the share price down. In fact, her personal share count is also being diluted, in order to pay the bills.
You can’t be serious Senti.
It’s not the same amount of shares if the stock price is higher. The higher the price, the less shares it is. If Linda owes Linda $100 and the stock price is $0.25 and wants to pay it in shares, it takes 400 shares to square up Linda. If the stock price is $1, it only takes 100 shares.
So Linda, thinking the stock price is going to get to $10 anyway, would naturally rather the price be $0.25 rather than $1, so she can get paid 400 shares and have $4000 later, rather than get paid 100 shares and only have $1000 later.
So again, you are wrong. Dilution is not the same. We’d be diluting much less if Linda had motive to get the share price up. But she doesn’t. She has incentive to keep the share price as low as possible, so she (Advent) can get as many shares as possible.
Additionally, the fact that Advent is willing to be paid in shares indicates... to me anyway... that they, Advent, are confident those shares will be worth more in the future.
It’s not Advent. It’s Linda. Linda is Advent. She is giving herself more shares. Her personal share count is not being diluted, it’s growing substantially.
It’s insane you can’t grasp what is going on here.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
